Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Once More Taro Takes Sun Pharma To Court; Alleges Failure To Disclose Information About U.S. FDA Action Against Caraco

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's Sun Pharmaceutical has more court battles to deal with as its takeover target Taro Pharmaceutical of Israel has filed one more case in a New York court alleging that its bidder failed to disclose "material information to Taro shareholders and unlawful use of confidential information.

You may also be interested in...



Israel Supreme Court Backs Sun Pharma For Taro Deal But Litigation May Not Be Over

MUMBAI - Sun Pharma's prolonged three-year battle to wrest control of Israeli generic drug maker Taro looks headed for a conclusion as the Israeli Supreme Court - after several months - allowed the Indian company to pursue purchase of outstanding shares, thereby dealing a blow to Taro's efforts to scuttle the takeover bid

Israel Supreme Court Backs Sun Pharma For Taro Deal But Litigation May Not Be Over

MUMBAI - Sun Pharma's prolonged three-year battle to wrest control of Israeli generic drug maker Taro looks headed for a conclusion as the Israeli Supreme Court - after several months - allowed the Indian company to pursue purchase of outstanding shares, thereby dealing a blow to Taro's efforts to scuttle the takeover bid

Sun Feels The Heat As FDA Seizes Caraco Drugs; To Sign Consent Decree And Reset Guidance

MUMBAI - Days after U.S. FDA ordered seizure of 33 products from Caraco's Detroit-based manufacturing unit, its Indian parent Sun Pharma told investors that it will withdraw its earnings guidance and revise at a later date. Sun Pharma had set a guidance of 13-15 percent growth in 2009-10

Related Content

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel